SCHEMBL21552948

SCHEMBL21552948

CC(C)(C)[Si](C)(C)OCC=Cc1cn(-c2ccc(C#N)cc2)c(=O)c(N2CCN(S(C)(=O)=O)CC2)n1

nearest known ligand 0.33

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ALK Q9UM73 1/20 0.32
EP300 Q09472 1/20 0.32
CYP17A1 P05093 2/20 0.31
CYP21A2 P08686 2/20 0.31
CYP11B1 P15538 2/20 0.31
HSD11B1 P28845 1/20 0.31
GBA1 P04062 1/20 0.30
CYP2D6 P10635 1/20 0.30
TSHR P16473 1/20 0.30
KDM1A O60341 1/20 0.30
GPR6 P46095 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21552946 1.00 KDM4E (0.33) KDM4EALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL21552872 0.90 CYP17A1 (0.35) ALDH1A1MAPTSMN1; SMN2CYP17A1CYP21A2
SCHEMBL21552870 0.90 CYP17A1 (0.35) ALDH1A1MAPTSMN1; SMN2CYP17A1CYP21A2
SCHEMBL21553029 0.89 TDP1 (0.37) ALDH1A1MAPTSMN1; SMN2HSD11B1TSHR
SCHEMBL21553027 0.89 TDP1 (0.37) ALDH1A1MAPTSMN1; SMN2HSD11B1TSHR
SCHEMBL21564856 0.88 KDM4E (0.37) KDM4EALDH1A1MAPTSMN1; SMN2
SCHEMBL26036642 0.86 KDM4E (0.33) KDM4EALDH1A1MAPTSMN1; SMN2KDM1A
SCHEMBL21552904 0.82 EGLN2 (0.33) EP300
SCHEMBL21552903 0.82 EGLN2 (0.33) EP300
SCHEMBL21552984 0.82 EP300 (0.33) KDM4EALDH1A1MAPTHPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3790867-B1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2024-03-27 EP disclosed
US-11932629-B2 KDM1A inhibitors for the treatment of disease IMAGO BIOSCIENCES, INC. (US) 2024-03-19 US disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed
EP-3790867-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2021-03-17 EP disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11932629-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A KDM4E 18/4885ALDH1A1 839/4885MAPT 4010/4885
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A KDM4E 18/4885ALDH1A1 839/4885MAPT 4010/4885
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A KDM4E 18/4885ALDH1A1 599/4885MAPT 4054/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A KDM4E 18/4885ALDH1A1 839/4885MAPT 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.